MDLN · Medline Inc. · Financials
Key customers — 74% of revenue (the year ended December 31, 2025)
“for the year ended December 31, 2025, approximately $19.7 billion (or 69% of consolidated net sales and 74% of U.S. net sales) was from sales to member hospitals under contract with our largest GPOs: Vizient Supply, LLC, HealthTrust Purchasing Group, L.P., and Premier Healthcare Alliance, L.P.”
Key customers — 69% of revenue (the year ended December 31, 2025)
“for the year ended December 31, 2025, approximately $19.7 billion (or 69% of consolidated net sales and 74% of U.S. net sales) was from sales to member hospitals under contract with our largest GPOs: Vizient Supply, LLC, HealthTrust Purchasing Group, L.P., and Premier Healthcare Alliance, L.P.”
5 customers — 11.3% of revenue (the year ended December 31, 2025)
“For the year ended December 31, 2025, our top five U.S. customers represented approximately $3.2 billion (or 11.3%) of our net sales.”
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| $28.43B | $25.51B | $23.23B | |
| $17M | $15M | $17M | |
| $20.91B | $18.53B | $17.35B | |
| $7.52B | $6.98B | $5.89B | |
| 26.44% | 27.35% | 25.33% | |
| $80M | $67M | $60M | |
| $4.52B | $4.11B | $3.87B | |
| $704M | $685M | $662M | |
| $1.01B | $977M | $951M | |
| $5.31B | $4.83B | $4.64B | |
| $2.21B | $2.15B | $1.25B | |
| 7.78% | 8.41% | 5.38% | |
| $3.22B | $3.12B | $2.2B | |
| $945M | $1.14B | $1.21B | |
| $133M | $280M | $237M | |
| -$964M | -$900M | -$986M | |
| $1.25B | $1.25B | $264M | |
| $91M | $46M | $30M | |
| $1.16B | $1.16B | $234M | |
| 4.08% | 4.56% | 1.01% | |
| -$2M | — | — | |
| $1.19B | $1.02B | $160M | |
| USD/shares | -$0.01 | — | — |
| USD/shares | -$0.01 | — | — |
| shares | 810M | — | — |
| shares | 810M | — | — |
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2023–FY2025: $53M in buybacks.
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Current debt and lease obligations | 2026-06-27 | USD 29,000,000 | 10-Q filed 2026-08-05 |
| Current operating lease liabilities | 2026-06-27 | USD 63,000,000 | 10-Q filed 2026-08-05 |
| Current portion of long-term debt | 2026-06-27 | USD 28,000,000 | 10-Q filed 2026-08-05 |
| Noncurrent debt carrying amount | 2026-06-27 | USD 12,548,000,000 | 10-Q filed 2026-08-05 |
| Short-term borrowings | 2026-06-27 | USD 1,000,000 | 10-Q filed 2026-08-05 |
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 15 similar-size Medical Instruments & Supplies companies (of 47 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Supply Chain Solutions Segment | $14,712,000,000 | $12,992,000,000 | $11,618,000,000 |
| Medline Brand Segment | $13,720,000,000 | $12,515,000,000 | $11,613,000,000 |
By Geography (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| United States | $26,479,000,000 | $23,747,000,000 | $21,800,000,000 |
| Non Us | $1,953,000,000 | $1,760,000,000 | $1,431,000,000 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Acute Care | $19,506,000,000 | $17,491,000,000 | $15,906,000,000 |
| Non-Acute Care | $6,973,000,000 | $6,256,000,000 | $5,894,000,000 |